Testing and treatment for latent tuberculosis infection are cost-effective among U.S. residents born outside the country except for those with end-stage renal disease, according to findings published in JAMA Internal Medicine.

New research found that a community-based strategy involving a nucleic-acid amplification test that can detect both Mycobacterium tuberculosis DNA and rifampicin resistance increased the rate of tuberculosis case detection and early treatment initiation.